Treatment of metastatic melanoma with pazopanib: A report of five patient cases
| Autor: | Laura F. Hutchins, Jill T. Johnson, Lindsey Dayer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Indazoles Metastatic melanoma Carboplatin Pazopanib Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Pharmacology (medical) neoplasms Melanoma Aged Sulfonamides business.industry Soft tissue sarcoma Cancer Treatment options Middle Aged medicine.disease Clinical Practice Pyrimidines Female business Stage iv medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 21(3) |
| ISSN: | 1477-092X |
| Popis: | Metastatic melanoma has a median length of survival after diagnosis of 6–9 months. Unfortunately, the National Comprehensive Cancer Network clinical practice guidelines for treating stage IV, unresectable, metastatic melanoma are limited with regard to treatment options. Pazopanib (Votrient™) is FDA-approved for advanced soft tissue sarcoma and advanced renal cell carcinoma. Limited research exists for using pazopanib in the treatment of metastatic melanoma. We present five cases in which pazopanib was used in combination with paclitaxel ± carboplatin for treatment of unresectable, metastatic melanoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|